Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01603849 : Prophylactic Cranial Irradiation in Patients With Lung Adenocarcinoma With High Risk of Brain Metastasis
PhasePhase 2
AgesMin: 18 Years Max: 60 Years
Inclusion Criteria:

- Patients with histologically proven advanced NSCLC (Stage IIIB or IV) who received
treatment either locoregional or systemic without progression at the end of it.

- Above 18 years and under 60 years of age

- General status with a Karnofsky >80%

- Eastern Cooperative Group (ECOG) ?2

- Negative CNS MRI at the beginning of any treatment

- Carcinoembryonic antigen > 20 ng/mL

- Hepatic and hematic cytology test within normal range

- Adequate renal function

- Those who accepted to participate in the study and who sign the letter of informed

Exclusion Criteria:

- Patients with another type of cancer

- Patients who refuse participate in the protocol

- General status with a Karnofsky <80%

- Eastern Cooperative Group (ECOG) >2

- Previous treatment with WBRT

- Previous treatment with chemotherapy

- Disease progression after initial treatment, either chemotherapy or chemoradiotherapy
depending the case.

- CNS metastasis at diagnosis

- Carcinoembryonic antigen < 20 ng/mL

- Abnormal laboratory test that interfere with chemotherapy administration
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557